ASMB
$28.53
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.
Recent News
Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates
Metagenomi Therapeutics (MGX) delivered earnings and revenue surprises of -4.35% and -54.84%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates
Personalis (PSNL) delivered earnings and revenue surprises of +16.13% and -4.66%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of +228.57% and +7.57%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
With 32% ownership, Assembly Biosciences, Inc. (NASDAQ:ASMB) has piqued the interest of institutional investors
Key Insights Institutions' substantial holdings in Assembly Biosciences implies that they have significant influence...
GILD Exercises Option to License Assembly Bio's Herpes Programs
Gilead exercises its option to license ASMB's HSV programs for developing long-acting candidates, ABI-1179 & ABI-5366, for recurrent genital herpes.